Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Five Eleven Pharma, Inc.
With
Indiana University
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male ≥ 18 years of age
Prostate cancer patients presenting with rising PSA after radical prostatectomy for treatment if primary disease.
PSA ≥ 0.2 ng/mL
Patients must give informed consent for the research study, and agree to allow investigator access to clinical results following treatment plan implementation such as description of the treatment plan and PSA values following implementation of treatment plan as part of standard care, typically determined 3-4 months after treatment.
Male ≥ 18 years of age
Histologically confirmed prostate cancer with following Gleason scoring at biopsy:
* Gleason ≥ 4+3 OR
* Gleason 3+4 with \>30% pattern 4 or ≥3 cores positive
Scheduled for radical prostatectomy (expected to occur within 60-days of scanning)
Patients must give informed consent for the research study, and agree to allow investigator access to the clinical results such as SOC imaging (mpMRI, e.g.) for surgical planning if done, or biopsy data following prostatectomy including lymph node dissection biopsy data, if available.
You may not be if
Inability to give informed consent.
Patient is unable to tolerate remaining still on the bed of the PET camera, due to physical limitations or claustrophobia.
Significant acute or chronic medical, neurologic, or illness in the subject that, in the judgment of the Clinical Investigators, could compromise subject safety, limit the ability to complete the study, and/or compromise the objectives of the study
Clareo Health | Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
